Navigation Links
Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference
Date:10/1/2009

elating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

www.echotx.com

    For More Information:
    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer
    (508)-530-0329

SOURCE Echo Therapeutics, Inc.


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Advanced Wound Dressings - SA Analysis ... have steadily replaced traditional bandages and gauze materials ... indications, such as trauma wounds, burns, and chronic ... protection become increasingly critical in wound healing, advanced ... This report focuses on nine market categories ...
(Date:9/2/2015)... 2015 About Duchenne muscular dystrophy ... generally affects the male population. It is characterized ... is caused due to mutations in the dystrophin ... of dystrophin (a protein essential for maintaining healthy ... weakens muscle function, causes loss of ambulation, harms ...
(Date:9/2/2015)... 2015   About ELISA test ELISA ... that is used for measuring the concentration of analytes ... uses various types of enzymes such as carbonic anhydrase, ... detected by photometry or fluorometry. ELISA is used as ... diseases such as HIV, pernicious anemia, rotavirus, Rocky Mountain ...
Breaking Medicine Technology:Advanced Wound Dressings - SA Analysis and Market Forecasts 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3
... Inc. (Hologic or the Company) (Nasdaq: HOLX ), ... medical imaging systems and surgical products dedicated to serving the ... first fiscal quarter ended December 25, 2010. ... million. Net income was $10.9 million, or $0.04 per ...
... Jan. 31, 2011 ImpactRx, a pioneer in ... behavior of physicians, completed its annual review of ... oncology offices.  The results have just been published ... Review. ImpactRx,s mobile pharmaceutical market research ...
Cached Medicine Technology:Hologic Announces First Quarter Fiscal 2011 Operating Results 2Hologic Announces First Quarter Fiscal 2011 Operating Results 3Hologic Announces First Quarter Fiscal 2011 Operating Results 4Hologic Announces First Quarter Fiscal 2011 Operating Results 5Hologic Announces First Quarter Fiscal 2011 Operating Results 6Hologic Announces First Quarter Fiscal 2011 Operating Results 7Hologic Announces First Quarter Fiscal 2011 Operating Results 8Hologic Announces First Quarter Fiscal 2011 Operating Results 9Hologic Announces First Quarter Fiscal 2011 Operating Results 10Hologic Announces First Quarter Fiscal 2011 Operating Results 11Hologic Announces First Quarter Fiscal 2011 Operating Results 12Hologic Announces First Quarter Fiscal 2011 Operating Results 13Hologic Announces First Quarter Fiscal 2011 Operating Results 14Hologic Announces First Quarter Fiscal 2011 Operating Results 15ImpactRx Releases 2010 Oncology Promotion Report 2
(Date:9/3/2015)... ... , ... “Love in Tokyo” an independent romantic comedy film by Michael Solton ... and will be released on DVD early next year, by Maverick Entertainment. The film ... and singer/songwriter, and Jason London, lead from “Dazed and Confused.” , “Love in ...
(Date:9/3/2015)... ... 03, 2015 , ... The new In-Office whitening kit from ... The Clinicians Report is a leading information source to the dental industry. Product ... Whiter Image's In-Office whitening kits were favorably validated for use in the dental ...
(Date:9/3/2015)... ... September 03, 2015 , ... About 220,800 new cases of prostate cancer are reported each ... be diagnosed with prostate cancer during their lifetime. While only one man in 10,000 will ... men by age 65, according to the American Cancer Society. , ...
(Date:9/3/2015)... MA (PRWEB) , ... September 03, 2015 , ... ... today announced that Bob Anders and Kelley Chapman will be joining the company’s ... , Anders has over 30 years’ experience in healthcare product and ...
(Date:9/3/2015)... ... ... Fashion designer Kim (29 years old, Honolulu, HI) designed her own successful ... ABC series “Extreme Weight Loss” Season 5 . Standing just 5’1” and weighing ... the motivation to transform when she designed a drop-dead-gorgeous dress and vowed she would ...
Breaking Medicine News(10 mins):Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 3
... team looking for a cure for Duchenne Muscular Dystrophy, an ... findings// recently. ,The Stem cell Studies done by ... those who suffer from the disease. ,Duchenne muscular ... that results in muscle wasting which usually begins in ...
... of a communiqué from Britain about a novel type of ... Britain’s research farm, New Zealand authorities// have requested exact details ... has detected the disease, which is technically called ‘scrapie’ that ... disease. ,Barry O'Neill, the man at the helm ...
... directions for mandatory HIV/ AIDS testing before taking up ... asked the Maharashtra government to consider framing a policy ... PIL filed by an NGO, Maharashtra Law Graduate Association., ... that the National AIDS Prevention and Control Policy of ...
... adopted a new policy it hopes will inspire Australians to ... of life, AMA President, Dr Mukesh Haikerwal,// said today. ... country, with a robust culture of physical activity and the ... trend is blotting our image as a fit and healthy ...
... the NGO, Madras Round Table 1, in an altruistic ... diseases. The novel// partnership has been named ‘Save A ... one child per day’ they aim to give underprivileged ... SACH aims to assist early diagnosis and availability of ...
... may have COPD (Chronic Obstructive Pulmonary Disease), a serious ... general term used for a number of respiratory conditions, ... be the main cause. Early symptoms of COPD include ... during exercise or exertion. ,The Global Initiative ...
Cached Medicine News:Health News:Advance Australia Active – AM 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: